1. Emerging and Evolving Concepts in Cancer Immunotherapy Imaging
- Author
-
Laurent Dercle, Shawn Sun, Romain-David Seban, Ahmed Mekki, Roger Sun, Lambros Tselikas, Sophie Hans, Alice Bernard-Tessier, Fadila Mihoubi Bouvier, Nicolas Aide, Laetitia Vercellino, Alexia Rivas, Antoine Girard, Fatima-Zohra Mokrane, Guillaume Manson, Roch Houot, Egesta Lopci, Randy Yeh, Samy Ammari, Lawrence H. Schwartz, Columbia University Medical Center (CUMC), Columbia University [New York], Institut Curie [Paris], Hôpital Raymond Poincaré [AP-HP], Radiothérapie Moléculaire et Innovation Thérapeutique (RaMo-IT), Institut Gustave Roussy (IGR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, TheraPanacea [Paris], Institut Gustave Roussy (IGR), Département d'imagerie médicale [Gustave Roussy], CHU Henri Mondor [Créteil], Département d’Innovation Thérapeutique et essais précoces [Gustave Roussy] (DITEP), AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Unité de recherche interdisciplinaire pour la prévention et le traitement des cancers (ANTICIPE), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER-Institut National de la Santé et de la Recherche Médicale (INSERM), Hopital Saint-Louis [AP-HP] (AP-HP), Centre Eugène Marquis (CRLCC), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Microenvironment and B-cells: Immunopathology,Cell Differentiation, and Cancer (MOBIDIC), Université de Rennes (UR)-Etablissement français du sang [Rennes] (EFS Bretagne)-Institut National de la Santé et de la Recherche Médicale (INSERM), Humanitas Clinical and Research Center [Rozzano, Milan, Italy], Memorial Sloan Kettering Cancer Center (MSKCC), Fondation ARC pour la recherche médicale (international mobility grant and grant SIGN’IC20161236437), INSERM, and Fondation Bettencourt Schueller, pending U.S. patent (no. 16630031), and Fondazione AIRC
- Subjects
[SDV]Life Sciences [q-bio] ,CLINICAL BENEFIT ,NIVOLUMAB ,MELANOMA ,ASSOCIATION ,HYPERPROGRESSIVE DISEASE ,GUIDELINES ,Neoplasms ,Positron-Emission Tomography ,Disease Progression ,Humans ,Immunologic Factors ,CRITERIA ,Radiology, Nuclear Medicine and imaging ,Immunotherapy ,IMMUNE-RELATED RESPONSE ,ADVERSE EVENTS ,INHIBITORS - Abstract
International audience; Criteria based on measurements of lesion diameter at CT have guided treatment with historical therapies due to the strong association between tumor size and survival. Clinical experience with immune checkpoint modulators shows that editing immune system function can be effective in various solid tumors. Equally, novel immune-related phenomena accompany this novel therapeutic paradigm. These effects of immunotherapy challenge the association of tumor size with response or progression and include risks and adverse events that present new demands for imaging to guide treatment decisions. Emerging and evolving approaches to immunotherapy highlight further key issues for imaging evaluation, such as dissociated response following local administration of immune checkpoint modulators, pseudoprogression due to immune infiltration in the tumor environment, and premature death due to hyperprogression. Research that may offer tools for radiologists to meet these challenges is reviewed. Different modalities are discussed, including immuno-PET, as well as new applications of CT, MRI, and fluorodeoxyglucose PET, such as radiomics and imaging of hematopoietic tissues or anthropometric characteristics. Multilevel integration of imaging and other biomarkers may improve clinical guidance for immunotherapies and provide theranostic opportunities.
- Published
- 2023
- Full Text
- View/download PDF